The effects of royal jelly for the adverse events of molecular target therapy for renal cancer patients.

The effects of royal jelly for the adverse events of molecular target therapy for renal cancer patients. - The effects of royal jelly for the adverse events of molecular target therapy for renal cancer patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020152

Enrollment

Registered

2015-12-15

Start date

2015-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

We examine this research using double-blind method. We divide the patients into two groups, royal jelly group and placebo-control group.The group of royal jelly patients take 2400mg /day royal jelly f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. renal cell carcinoma patient 2. performance status 0-1 3. WBC 3000/mm3 <= Neutro:1500/mm3 <= PLT:100,000/mm3 <= Hb:8g/dl <= AST and ALT:Upper limit 3 times or less T.Bil:1.5mg/dl => Crea:2.0mg/dl => FB:125mg/dl => 4. Those who can start this research within two weeks after resistration. 5. those who are 20 years and older 6. those who allow the participation for this study

Exclusion criteria

Exclusion criteria: 1. those who have possibility of the cancer death within six months 2.those who have allergy for honey 3. those who have some allergy for foods and drugs 4. those who have another cancer

Design outcomes

Primary

Measure	Time frame
The efficacy of royal jelly for the skin problem of the molecular target therapy.	—

Countries

Japan

Contacts

Public ContactTomohiro Matsuo

Nagasaki University Hospital Urology and Renal transplantation

tomo1228@nagasaki-u.ac.jp095-819-7340

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026